PMC:7195088 / 33621-34332 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T44","span":{"begin":23,"end":27},"obj":"Body_part"},{"id":"T45","span":{"begin":23,"end":25},"obj":"Body_part"},{"id":"T46","span":{"begin":38,"end":42},"obj":"Body_part"},{"id":"T47","span":{"begin":38,"end":40},"obj":"Body_part"},{"id":"T48","span":{"begin":124,"end":132},"obj":"Body_part"},{"id":"T49","span":{"begin":237,"end":245},"obj":"Body_part"},{"id":"T50","span":{"begin":446,"end":450},"obj":"Body_part"},{"id":"T51","span":{"begin":446,"end":448},"obj":"Body_part"}],"attributes":[{"id":"A44","pred":"fma_id","subj":"T44","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A45","pred":"fma_id","subj":"T45","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A46","pred":"fma_id","subj":"T46","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A47","pred":"fma_id","subj":"T47","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A48","pred":"fma_id","subj":"T48","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A49","pred":"fma_id","subj":"T49","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A50","pred":"fma_id","subj":"T50","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A51","pred":"fma_id","subj":"T51","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"Anakinra Antagonist of IL-1 receptor. IL-1 is one of the main drivers of immunologic response and symptoms in patients with cytokine-release syndrome. • Not available • Comparison of anakinra vs. emapalumab (anti–interferon γ monoclonal antibody) vs. standard of care in patients with COVID-19. Open-label RCT (NCT04324021, not yet recruiting). Primary endpoint: treatment success at day 15.\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T33","span":{"begin":124,"end":149},"obj":"Phenotype"}],"attributes":[{"id":"A33","pred":"hp_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"Anakinra Antagonist of IL-1 receptor. IL-1 is one of the main drivers of immunologic response and symptoms in patients with cytokine-release syndrome. • Not available • Comparison of anakinra vs. emapalumab (anti–interferon γ monoclonal antibody) vs. standard of care in patients with COVID-19. Open-label RCT (NCT04324021, not yet recruiting). Primary endpoint: treatment success at day 15.\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T174","span":{"begin":285,"end":293},"obj":"Disease"},{"id":"T175","span":{"begin":584,"end":592},"obj":"Disease"}],"attributes":[{"id":"A174","pred":"mondo_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A175","pred":"mondo_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Anakinra Antagonist of IL-1 receptor. IL-1 is one of the main drivers of immunologic response and symptoms in patients with cytokine-release syndrome. • Not available • Comparison of anakinra vs. emapalumab (anti–interferon γ monoclonal antibody) vs. standard of care in patients with COVID-19. Open-label RCT (NCT04324021, not yet recruiting). Primary endpoint: treatment success at day 15.\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T189","span":{"begin":300,"end":305},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T190","span":{"begin":599,"end":604},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Anakinra Antagonist of IL-1 receptor. IL-1 is one of the main drivers of immunologic response and symptoms in patients with cytokine-release syndrome. • Not available • Comparison of anakinra vs. emapalumab (anti–interferon γ monoclonal antibody) vs. standard of care in patients with COVID-19. Open-label RCT (NCT04324021, not yet recruiting). Primary endpoint: treatment success at day 15.\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T456","span":{"begin":23,"end":25},"obj":"Chemical"},{"id":"T458","span":{"begin":38,"end":40},"obj":"Chemical"},{"id":"T460","span":{"begin":213,"end":223},"obj":"Chemical"},{"id":"T461","span":{"begin":300,"end":305},"obj":"Chemical"},{"id":"T462","span":{"begin":408,"end":419},"obj":"Chemical"},{"id":"T463","span":{"begin":446,"end":448},"obj":"Chemical"},{"id":"T465","span":{"begin":460,"end":470},"obj":"Chemical"},{"id":"T466","span":{"begin":534,"end":545},"obj":"Chemical"},{"id":"T467","span":{"begin":599,"end":604},"obj":"Chemical"}],"attributes":[{"id":"A456","pred":"chebi_id","subj":"T456","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A457","pred":"chebi_id","subj":"T456","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A458","pred":"chebi_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A459","pred":"chebi_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A460","pred":"chebi_id","subj":"T460","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A461","pred":"chebi_id","subj":"T461","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A462","pred":"chebi_id","subj":"T462","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A463","pred":"chebi_id","subj":"T463","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A464","pred":"chebi_id","subj":"T463","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A465","pred":"chebi_id","subj":"T465","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A466","pred":"chebi_id","subj":"T466","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A467","pred":"chebi_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"Anakinra Antagonist of IL-1 receptor. IL-1 is one of the main drivers of immunologic response and symptoms in patients with cytokine-release syndrome. • Not available • Comparison of anakinra vs. emapalumab (anti–interferon γ monoclonal antibody) vs. standard of care in patients with COVID-19. Open-label RCT (NCT04324021, not yet recruiting). Primary endpoint: treatment success at day 15.\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T270","span":{"begin":0,"end":37},"obj":"Sentence"},{"id":"T271","span":{"begin":38,"end":294},"obj":"Sentence"},{"id":"T272","span":{"begin":295,"end":344},"obj":"Sentence"},{"id":"T273","span":{"begin":345,"end":391},"obj":"Sentence"},{"id":"T274","span":{"begin":392,"end":593},"obj":"Sentence"},{"id":"T275","span":{"begin":594,"end":643},"obj":"Sentence"},{"id":"T276","span":{"begin":644,"end":711},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Anakinra Antagonist of IL-1 receptor. IL-1 is one of the main drivers of immunologic response and symptoms in patients with cytokine-release syndrome. • Not available • Comparison of anakinra vs. emapalumab (anti–interferon γ monoclonal antibody) vs. standard of care in patients with COVID-19. Open-label RCT (NCT04324021, not yet recruiting). Primary endpoint: treatment success at day 15.\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days)."}